Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulevirtide in Chronic Hepatitis Delta (MYR301)
NCT03852719Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of bulevirtide in hepatitis D (HDV), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With Combined Response (Undetectable HDV RNA or >= 2 log decline AND ALT normalization) at Week 48. Started Apr 2019; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT03852719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852719.